Download Presentation Title

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
Transcript
Breast Cancer Risk and Risk
Assessment Models
Jessica Ray, MS, CGC
Cancer Genetic Counselor
Ambry Genetic Laboratories
[email protected]
¡Vida! Educational Series - Promoting Good Health
Learning Objectives
• Identify Personal and Family Characteristics
that may indicate an inherited increased risk
for cancer
• Understand the role of genetic counseling in
assessing patients with possible hereditary
cancer syndromes
• Understand characteristics, advantages,
limitations, and differences of the Gail and
BRCAPRO risk-assessment tools used by
clinicians to help establish cancer risk
Who Is at “High Risk”?
• Atypia
• 5-year Gail risk >1.7%
• 2 or more 2nd-degree premenopausal
affected relatives
• Combined estrogen-progesterone hormone
therapy for more than 10 years
• Mammographically dense breasts
• Obesity
Who Is at “Very High Risk”?
•
•
•
•
•
Personal history of BC <50
BRCA1 or BRCA2 mutation carrier
2 or more 1st-degree relatives with BC
Lobular carcinoma in situ (LCIS)
Atypia and a 1st-degree relative with BC
What is Genetic Counseling?
Genetic Counseling is a
communication process that
deals with both the medical
and psychological issues
associated with the
occurrence of a genetic
disorder in a family
• Cancer genetic counseling
focuses on hereditary
cancer syndromes
• This process involves one or
more trained professionals
to help the individual or
family
Reasons for Seeking
Genetics Consultation
• To learn about
•
•
•
•
Personal risk for cancer
Children’s risk for cancer
Family’s risk for cancer
Risks for developing cancer if you have a “cancer
gene”
• Recommendations for screening, surveillance,
and/or treatment
• Educational information
• To obtain genetic DNA testing
J Med Genet 2000; 37:866-874
Key Flags that
Warrant Genetic Counseling
• Significant family medical history-breast, ovarian,
prostate, colon, uterine, melanoma, pancreatic, or other
cancers
• Cancer occurs in every generation
• Early age of onset (< 50 years)
• Male breast cancer
• Bilateral cancer, or multiple primary cancers in one
individual
• Known family genetic mutation
• Ethnicity – Ashkenazi Jewish ancestry
Sporadic, Familial or Hereditary?
• 5-10% cancers have a hereditary component
• Over 200 hereditary cancer syndromes described
• Hereditary cancer tends to occur at younger ages
than sporadic cancer, often bilateral, multifocal
• Lifetime risks of cancer exceed cancer risks due to
noninherited factors (early menarche, nulliparity,
late age of menopause, HRT, etc)
• Majority show an autosomal dominant inheritance
pattern (few are recessive)
Average Age of Diagnosis
Hereditary
• Breast
41
• Ovarian 40-50
• Prostate
63
Sporadic
• Breast
• Ovarian
• Prostate
62
60
71
Gail Model
National Cancer Institute http://www.cancer.gov/bcrisktool/Default.aspx
Gail Model: Advantages
• Identifies women who could benefit from preventive
interventions; may assist in making clinical decisions
(Determination of eligibility for tamoxifen for breast cancer risk
reduction…Gail score>1.7)
• Incorporates risk factors other than family history (eg,
reproductive variables, atypical hyperplasia, history of breast
biopsies)
• Calculation of breast cancer risk in absence of family history in
women
• Shows that BC risk increases with age and, therefore, may
prompt discussion about the importance of BC screening
• Used to counsel and educate women, especially those who
overestimate their BC risk
Gail Model: Limitations
• Not validated for black, Hispanic, and other ethnic
groups
• Only solicits family history involving first-degree
relatives
• May underestimate risk when family history is on
father’s side
• Does not take into account age at which relatives
developed BC
• Effect of number of breast biopsies (without atypical
hyperplasia) may cause inflated risk estimates
• May underestimate risk for women with demonstrated
mutations of the BRCA1 or BRCA2 genes
BRCAPRO - Advantages
• Incorporates both affected and unaffected family
members in estimation of carrier probability
• incorporates maternal and paternal breast and ovarian
cancer history
• age at cancer diagnosis, current ages, ages relatives
became deceased considered
• Ashkenazi Jewish ethnicity taken into consideration
• Oophorectomy status and breast cancer receptor status
considered
BRCAPRO - Limitations
• Dependent on published estimates of prevalence and
penetrance of BRCA1 and BRCA2
• Does not consider more distant family history past 1st
and 2nd degree relatives
• Does not consider other potential susceptibility genes
with features similar to BRCA1 and BRCA2
When Do You Offer Testing?
• American Society of Clinical Oncology recommends genetic testing :
• The individual has a personal or family history of features
suggestive of a genetic cancer susceptibility condition
• The test can be adequately interpreted
• The results will aid in diagnosis or influence the medical or
surgical management of the patient or family members at
hereditary risk of cancer
ASCO recommendations:
• Genetic testing only be done in the setting of pre-and post-test
counseling,
• Should discuss possible risks and benefits of cancer early detection and
prevention modalities
Implications/Important Points
• What do we offer individuals at high risk for
hereditary cancers who test negative for a genetic
mutation?
• Negative genetic test result does not mean No
Increased Risk!!
• AZCC High Risk Clinic for individuals at greater risk
of developing cancer
• Must continue studies to find other genes responsible
for hereditary cancers
• Must develop more advanced, individualized risk
assessment tools